GYPC

Across TCGA pan-cancer cohorts, GYPC mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GYPC data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GYPC mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GYPC expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where GYPC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.895	0.991	.006	25	view →
CCRCC	DFS	Median	All	0.915	0.567	.010	7	view →
LUAD	OS	Median	II,III,IV	0.803	0.479	.019	5	view →
LSCC	DFS	Median	II,III,IV	0.866	0.965	.034	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GYPC–HNSC (DFS)

Open the HNSC breakdown →